Clinical efficacy and effectiveness of Sativex^®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity

References

• Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil.24, 293–304 (2010).
   PubMed Web of Science ®Google Scholar
• Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler.10, 589–595 (2004).
   PubMed Web of Science ®Google Scholar
• Sosnoff JJ, Gappmaier E, Frame A, Motl RW. Influence of spasticity on mobility and balance in persons with multiple sclerosis. J. Neurol. Phys. Ther.35, 129–132 (2011).
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev.2, CD001332 (2004).
   Google Scholar
• Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev. Pharmacoecon. Outcomes Res.11, 205–213 (2011).
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, González D, Vila C, de Sola S. Multiple sclerosis spasticity in Spain: the 6E patients’ survey. Mult. Scler.17(Suppl. 10), S80 (2011).
   Google Scholar
• Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther.30, 974–985 (2008).
   PubMed Web of Science ®Google Scholar
• Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult. Scler.12, 646–651 (2006).
   PubMed Web of Science ®Google Scholar
• Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today42, 495–501 (2006).
   PubMed Web of Science ®Google Scholar
• Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract.59, 291–295 (2005).
   PubMed Web of Science ®Google Scholar
• Russo EB. Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag.4, 245–249 (2008).
   PubMedGoogle Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol.147, S163–S171 (2006).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol.18, 129–140 (2007).
   PubMed Web of Science ®Google Scholar
• Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol.150, 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol.15(Suppl. 3), 365 (2008).
   Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol.14, 290–296 (2007).
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res.32, 451–459 (2010).
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol.18, 1122–1131 (2011).
   PubMed Web of Science ®Google Scholar
• Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler.13, S129 (2007).
   Google Scholar
• Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler.12, 639–645 (2006).
   PubMed Web of Science ®Google Scholar
• Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler.16, 707–714 (2010).
   PubMed Web of Science ®Google Scholar
• Montalbán X, Sastre Garriga J, Vila C, Clissold SP. THC and CBD oromucosal spray (Sativex) in the management of spasticity associated with multiple sclerosis. Expert Rev. Neurother.11, 627–637 (2011).
   PubMedGoogle Scholar
• Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who were receiving long term Sativex® (nabiximols). Mult. Scler.18(2), 219–228 (2012).
   PubMed Web of Science ®Google Scholar
• Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler.10, 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Montalbán X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler.15, S272 (2009).
   PubMed Web of Science ®Google Scholar
• House H, Bateman C, Wade DT. Long-term Sativex (THC:CBD) use in multiple sclerosis: benefits to daily life and functional activities. Mult. Scler.13, S267 (2007).
   Google Scholar